Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

JOHNSON & JOHNSON

(JNJ)
  Report
Delayed Nyse  -  01:00 2022-11-25 pm EST
177.24 USD   +0.13%
11/23Sector Update: Health Care Stocks Advancing Wednesday Afternoon
MT
11/23Sector Update: Health Care Stocks Still Advancing in Wednesday Trading
MT
11/23Sector Update: Health Care
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Johnson & Johnson To Discontinue Selling Talc-Based Baby Powder In 2023

08/12/2022 | 06:37am EST


ę MT Newswires 2022
All news about JOHNSON & JOHNSON
11/23Sector Update: Health Care Stocks Advancing Wednesday Afternoon
MT
11/23Sector Update: Health Care Stocks Still Advancing in Wednesday Trading
MT
11/23Sector Update: Health Care
MT
11/23Correction: Fed Minutes Eyed for Signs of Slower Fed Rate Hikes as ETFs, Stoc..
MT
11/23Fed Minutes Eyed for Signs of Slower Fed Rate Hikes as ETFs, Stock Futures Inch Higher ..
MT
11/23Johnson & Johnson's Janssen Pharmaceutical Says Phase 3 Trial of Major Depressive Disor..
MT
11/21Insider Sell: Johnson & Johnson
MT
11/21JOHNSON & JOHNSON : Ex-dividend day for
FA
11/18Vaccines and drugs in the pipeline for RSV
RE
11/18Markets are still on a roller coaster ride
MS
More news
Analyst Recommendations on JOHNSON & JOHNSON
More recommendations
Financials (USD)
Sales 2022 95 045 M - -
Net income 2022 20 677 M - -
Net cash 2022 10 194 M - -
P/E ratio 2022 22,3x
Yield 2022 2,46%
Capitalization 463 B 463 B -
EV / Sales 2022 4,77x
EV / Sales 2023 4,54x
Nbr of Employees 141 700
Free-Float 83,8%
Chart JOHNSON & JOHNSON
Duration : Period :
Johnson & Johnson Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Last Close Price 177,24 $
Average target price 181,36 $
Spread / Average Target 2,33%
EPS Revisions
Managers and Directors
Joaquin Duato Chief Executive Officer & Director
Joseph J. Wolk Chief Financial Officer & Executive Vice President
Matthew Stuckley Senior Financial Analyst-Janssen Commercial Pharm
Alex Gorsky Executive Chairman
Peter Shen Global Head-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
JOHNSON & JOHNSON3.61%463 391
ELI LILLY AND COMPANY30.95%347 052
ABBVIE INC.17.89%282 189
PFIZER, INC.-16.66%276 231
MERCK & CO., INC.40.27%272 555
ROCHE HOLDING AG-17.86%270 482